Abstract 2951
Background
We previously showed pTMB selects patients (pts) deriving benefit from PD-L1 and CTLA-4 inhibition with durvalumab and tremelimumab (D+T) compared to best supportive care (BSC) in refractory mCRC in CCTG CO.26.
Methods
We investigated somatic variants contributing to pTMB in MSS pts using cell-free DNA (cfDNA) analysis performed with the GuardantOMNITMassay (2.1Mb) on 166 pts from CO.26.
Results
Median pTMB was 16.3 mutations/megabase (mts/Mb). Using a minimum p-value approach, pts with pTMB>28 mts/Mb (21% of MSS pts) had the greatest overall survival (OS) benefit for D + T (HR 0.34, 90% CI 0.18-0.63, p-interaction=0.070) and worse OS in the BSC arm (HR 2.59, 90% CI 1.46-4.62). Of 4044 mts detected, 2718 (67.2%) were subclonal (<10% of max detected mutant allele frequency [MAF]). Anti-EGFR exposure associated with more mts per pt (median 28.5 vs 15.5, P < 0.0001), higher proportion of subclonal mts (78.3% vs 53.7%, P < 0.0001) and higher median pTMB compared to RAS mt pts with no prior anti-EGFR (24.9 vs 13.4 mts/Mb, P < 0.0001). After removing subclonal mts from pTMB calculation, median pTMB decreased to 5.8 mts/Mb. This clonal pTMB remained predictive of D+T improving OS (HR 0.19, 90% CI 0.08-0.45, p-interaction=0.039) when pTMB>10.6 mts/Mb (14.1% pts). Similarly, pTMB calculated using only subclonal mts associated with D+T OS benefit (HR 0.32, 90% CI 0.16-0.67, p-interaction=0.057). Though many genes were associated with pTMB and improved efficacy (see Table), only BRCA1 mts predicted treatment effect (p-interaction=0.035). Most DNA repair mts were subclonal and not associated with increased clonal pTMB.Table:
528PD
Gene Mutation | Median pTMB MT vs WT | Median Clonal pTMB MT vs WT | HR (90% CI, p) Among Pts with Selected MT |
---|---|---|---|
MSS Study Population (n = 166) | 16.3 (95% CI: 14.4-20.1) | 5.8 (95% CI: 4.8-5.8) | 0.66 (0.49-0.89, 0.024) |
BRCA1 (n = 21) | 23.0 vs 15.3 (P = 0.0006) | 5.8 vs 5.8 (P = 0.64) | 0.20 (0.07-0.58, 0.013) |
BRCA2 (n = 29) | 28.9 vs 14.6 (P < 0.0001) | 5.8 vs 5.8 (P = 0.52) | 0.39 (0.18-0.85, 0.047) |
ATM (n = 31) | 31.6 vs 13.9 (P < 0.0001) | 6.7 vs 4.8 (P = 0.023) | 0.66 (0.37-1.18, 0.24) |
Polymerase E/D1/Q/H (n = 20) | 36.4 vs 14.7 (P < 0.0001) | 5.3 vs 5.8 (P = 0.57) | 0.95 (0.44-2.05, 0.91) |
TP53 (n = 126) | 17.2 vs 13.1 (P = 0.024) | 4.8 vs 6.7 (P = 0.017) | 0.63 (0.45-0.88, 0.024) |
MMR Gene without MSI (n = 31) | 24.9 vs 14.6 (P < 0.0001) | 5.8 vs 5.8 (P = 0.85) | 0.38 (0.17-0.85, 0.050) |
Conclusions
Both clonal and subclonal mts causing an elevated pTMB associated with benefit from D+T and mts in select DNA repair genes may correlate with benefit. cfDNA provides an opportunity to evaluate tumor evolution potentially missed in archival tissue.
Clinical trial identification
NCT02870920.
Editorial acknowledgement
Legal entity responsible for the study
Canadian Cancer Trials Group.
Funding
Canadian Cancer Society.
Disclosure
P.Z. Brohawn: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. K. Banks: Shareholder / Stockholder / Stock options, Licensing / Royalties, Full / Part-time employment: Guardant Health. K. Quinn: Shareholder / Stockholder / Stock options, Licensing / Royalties, Full / Part-time employment: Guardant Health. All other authors have declared no conflicts of interest.
Resources from the same session
Poster Discussion – Gastrointestinal tumours, colorectal - Invited Discussant 528PD, 529PD, 530PD and 531PD
Presenter: Pia Österlund
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Slides
Webcast
Poster Discussion – Gastrointestinal tumours, colorectal - Invited Discussant 532PD and 533PD
Presenter: Demetris Papamichael
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Slides
Webcast